Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

Annals of Oncology

Volumn 26, Issue 12, 2015, Pages 2429-2436

  Bianchini, G ^a   Pusztai, L ^b   Pienkowski, T ^c   Im, Y H ^d   Bianchi, G V ^e   Tseng, L M ^f   Liu, M C ^g   Lluch, A ^h   Galeota, E ^a   Magazzu D ⁱ   de la Haba Rodriguez J ^j   Oh, D Y ^k   Poirier, B ^l   Pedrini, J L ^m   Semiglazov, V ⁿ   Valagussa, P ⁱ   Gianni, L ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b YALE CANCER CENTER   (United States)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Samsung Medical Center   (South Korea)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ Fondazione Michelangelo   (Italy)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k Seoul National University Hospital   (South Korea)

^l LAVAL UNIVERSITY   (Canada)

^m HOSPITAL ERNESTO DORNELLES   (Brazil)

ⁿ N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

more..

Author keywords

Breast cancer; Gene expression; Immune system; Pertuzumab; Predictive marker; Trastuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; ONCOPROTEIN; PERTUZUMAB; PROTEIN PDL 1; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CTLA4 GENE; GENE; GENE EXPRESSION; HUMAN; IF 1 GENE; IFNG GENE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MHC1 GENE; MHC2 GENE; PD1 GENE; PDL1 GENE; PDL2 GENE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAT1 GENE; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELLULAR IMMUNITY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MIDDLE AGED; NEOADJUVANT THERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TRASTUZUMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84949965164     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv395     Document Type: Article

References (35)

1. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
2. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibodybased immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28: 4390-4399.
3. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014; 15: e58-e68.
4. Prat A, Bianchini G, Thomas M, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH Study. Clin Cancer Res 2014; 20: 511-521.
5. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
6. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
7. Bianchini G, Iwamoto T, Qi Y, et al. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 2010; 70: 8852-8862.
8. Bianchini G, Qi Y, Alvarez RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010; 28: 4316-4323.
9. Rody A, Holtrich U, Pusztai L, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009; 11: R15.
10. Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in her2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the neoaltto trial. JAMA Oncol 2015; 1: 448-454.
11. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
12. Bianchini G, Prat A, Pickl M, et al. Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER-HER2-positive breast cancers: gene expression analysis. J Clin Oncol 2011. ASCO Annual Meeting Proceedings (Post-Meeting Edition). Abst: 529.
13. Borgerding A, Hasenkamp J, Engelke M, et al. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp Hematol 2010; 38: 213-221.
14. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). San Antonio Breast Cancer Symposium (S1-05) 2013.
15. Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011; 108: 7142-7147.
16. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30: 1996-2004.
17. Cordon-Cardo C, Fuks Z, Drobnjak M, et al. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991; 51: 6372-6380.
18. Slaney CY, Rautela J, Parker BS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res 2013; 73: 5852-5857.
19. Bidwell BN, Slaney CY, Withana NP, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012; 18: 1224-1231.
20. Brooks AG, Boyington JC, Sun PD. Natural killer cell recognition of HLA class I molecules. Rev Immunogenet 2000; 2: 433-448.
21. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
22. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
23. Zaidi MR, Merlino G. The two faces of interferon-? in cancer. Clin Cancer Res 2011; 17: 6118-6124.
24. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
25. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13: 227-242.
26. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 2013; 5: 200ra116.
27. Bo T, Jonassen I. New feature subset selection procedures for classification of expression profiles. Genome Biol 2002; 3: RESEARCH0017.
28. Pagès F. Tumor-associated immune parameters for personalized patient care. Sci Transl Med 2013; 5: 214fs242.
29. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-116.
30. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84-88.
31. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128.
32. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2015; 8: 783.
33. Cha E, Klinger M, Hou Y, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 2014; 6: 238ra270.
34. Wang Q, Li S-H, Wang H, et al. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res 2012; 72: 4417-4428.
35. Yang X, Zhang X, Fu ML, et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 2014; 25: 37-48.